PTX

PRESCIENT FPO [PTX]
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0800 +9.6%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when PTX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PTX — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Trading above both moving averages — the trend is your friend here
  • Beating the Small Ords index — relative strength of 1.43, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Adequate cash runway (5 quarters)
  • 4C filed 2026-04-29
  • EPS estimates revised upward (+10pts)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Positive long-term momentum — up 40% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.57%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Revenue declining (-7%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-208%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about PTX
"What's driving PTX today?" "How does PTX compare to peers?" "Key risks for PTX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification of cessation of securities - PTX
NONE PTX Dr Rosalind Wilson appointed as Chief Medical Officer
Announcement tone +3pts

Recent ASX Announcements

2026-07-10 Notification of cessation of securities - PTX
2026-06-11 PTX Dr Rosalind Wilson appointed as Chief Medical Officer

Key Metrics

$76.8M
Market Cap
899K
Avg Volume
1.0x
Vol Ratio
$0.04 — $0.12
52-Week Range
N/A
Short Interest
5 qtrs
Cash Runway
-54.3%
ROE
-207.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 88%
LLeader vs LaggardpassRS: 13
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:PTX vs ECSPTX vs VHLPTX vs NTI
Scout Pro — Deeper Analysis for PTX
Try Pro free for 30 days
Share this analysis

Track PTX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required